Supernus Pharmaceuticals Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Supernus Pharmaceuticals Bundle
Download Your Competitive Advantage
Supernus Pharmaceuticals is at an inflection point — this preview maps which products are pulling weight and which are draining cash, but the full BCG Matrix gives you quadrant-by-quadrant clarity and actionable strategy. Get the complete report to see exact placements, data-driven recommendations, and where to shift investment next. Purchase now for a ready-to-use Word report plus an Excel summary you can plug into your board materials. Skip the guesswork—get the full picture and act with confidence.
Stars
Qelbree (ADHD non‑stimulant)
Qelbree has seen fast uptake in the expanding ADHD market (US ADHD prescription market >$12B in 2024), gaining share as a differentiated non‑stimulant with broad‑age labeling and a strong safety/low abuse profile; high promotion intensity (field + DTC) has driven double‑digit share gains year‑over‑year, so continued investment in field and consumer marketing is warranted to cement leadership as the class grows.
Parkinson’s portfolio leaders (e.g., amantadine ER, apomorphine)
Parkinson’s portfolio leaders like amantadine ER and apomorphine have strong brand recognition in movement‑disorder clinics and show real clinical differentiation in reducing dyskinesia and OFF time. Parkinsons affects ~10 million people worldwide and ~1 million in the US, projected to reach ~1.2 million by 2030, supporting category expansion. Capturing demand requires heavy patient‑support programs and specialty distribution; sustaining access and adding clinical/outcomes data will compound revenue growth.
Neurology KOL footprint
Deep KOL relationships with epilepsy specialists (epilepsy affects ~50 million people globally, WHO) and movement‑disorder experts (Parkinsons ~10 million, WHO) accelerate adoption across Supernus brands. Expanding a call universe of ~16,000 US neurologists (AAN) increases pull‑through and Rx volume. Sustained medical education and evidence generation are required to defend share, which then converts into a growth flywheel.
Label/indication expansion engines
Label and indication expansions (line extensions) increase volume while preserving Supernus core CNS science; each approval or supplemental NDA in 2024 lifted product-level share during a neurology market growing roughly 5% YoY, making incremental ROI attractive despite upfront cash and multi-year trials.
Maintain a warm pipeline of supplemental filings and Phase II/III studies to sustain share gains; typical play requires high near-term spend but delivers above-cost-of-capital returns when category growth persists.
- line-extensions
- new-indications
- pipeline-warmth
- 5%-market-growth-2024
- attractive-ROI
Patient services that remove friction
Patient services that remove friction—access, affordability, adherence—drive persistency in Supernus growth categories and position these products as Stars in the BCG matrix. IQVIA 2024 found adherence programs raise medication persistency by ~20%, translating to higher effective share and revenue capture. These white‑glove programs cost (industry benchmark 5–8% of product revenue) but unlock sustained demand; maintain premium support to stay ahead.
- Access: streamline prior auth and distribution
- Affordability: co‑pay assistance reduces abandonment
- Adherence: ~20% persistency uplift (IQVIA 2024)
Non‑stimulant gains rapid share in >$12B US ADHD market; patient services lift persistence
Qelbree drives rapid share in the >$12B US ADHD market (2024) as a differentiated non‑stimulant; continued field+DTC spend supports double‑digit YoY growth. Parkinsons portfolio (US ~1M patients, 2024) and epilepsy (global ~50M) show durable clinic pull‑through with specialty access needs. Patient services lift persistency ~20% (IQVIA 2024) at 5–8% revenue cost, justifying investment to keep these assets as Stars.
| Metric | 2024 / Value |
|---|---|
| US ADHD market | $12B |
| US Parkinsons prevalence | ~1M |
| Global epilepsy | ~50M |
| Adherence uplift | ~20% (IQVIA 2024) |
| Support cost | 5–8% of revenue |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Supernus Pharmaceuticals: identifies Stars, Cash Cows, Question Marks, Dogs with strategic investment guidance.
Customizable Excel Spreadsheet
One-page BCG matrix for Supernus Pharmaceuticals, pinpointing pain points and prioritizing units for faster decisions.
Cash Cows
Epilepsy XR franchise (mature, high share)
Epilepsy XR franchise (mature, high share) sustained >1.0 million prescriptions in 2024 with high patient retention and predictable refill cadence, supporting stable cash flow. Category growth was modest at ~3% in 2024 while gross margins remained healthy near 40%, keeping contribution margins strong. Lower promotional needs keep opex light; prioritize optimizing sampling and payer contracting and keep milking the base.
Long‑tenured PD brands with loyal users
Long‑tenured PD brands show stable prescriber habits and consistent outcomes that protect a book delivering steady cash: Supernus reported roughly $1.2B in 2024 product sales, with limited volume growth but solid gross profit per script supporting margins near mid‑30s percent. Focus is on access maintenance rather than heavy expansion, and incremental efficiencies flow directly to cash flow, boosting free cash conversion.
U.S. specialty distribution channels
U.S. specialty distribution channels
Supernus' well‑oiled distribution minimizes leakage and returns, sustaining fill rates above 95% and return rates below 3% in 2024. The network is built and amortized, making incremental units high margin and funding 2024 R&D and BD investments. Tight SLAs and lean inventory improved working capital, freeing cash to back higher‑risk pipeline bets.
Core payer contracts
Core payer contracts are locked into formulary positions that reduce churn and rebate volatility; with top PBMs managing approximately 75% of US prescriptions, 2024 renegotiations prioritized stability over splash. Small contractual tweaks—duration, price protection, specialty carve-outs—yield outsized cash uplift and steadier free cash flow. Protect these cash cows with targeted account management and monthly performance analytics.
Lifecycle‑managed SKUs
Lifecycle‑managed SKUs rely on packaging, dosing tweaks and minor enhancements to sustain demand with low incremental spend; they do not drive growth but generate steady cash flow. Supply reliability is the primary value lever, so keep COGS low and quality controls stringent to protect margins and uptime.
- Role: cash generators
- Driver: supply reliability
- Focus: COGS down, quality up
- Investment: minor, high ROI
>1M scripts, ~40% margin, PBM reach ~75%
Epilepsy XR >1.0M scripts in 2024 with gross margin ~40%, low promo spend and predictable refills sustaining cash flow. PD brands contributed to ~ $1.2B product sales in 2024 with mid‑30s% margins, focusing on access retention. Distribution fill rates >95% and returns <3% cut leakage; top PBMs cover ~75% of US scripts, protecting steady free cash flow.
| Metric | 2024 |
|---|---|
| Epilepsy XR scripts | >1.0M |
| Product sales | $1.2B |
| Gross margin | ~40% |
| Fill rate | >95% |
| Return rate | <3% |
| PBM reach | ~75% |
Preview = Final Product
Supernus Pharmaceuticals BCG Matrix
The file you're previewing is the exact Supernus Pharmaceuticals BCG Matrix you'll receive after purchase—no watermarks, no demo pages. It's fully formatted, market-informed, and ready to drop into your strategy decks. Buy once, download immediately, edit, print, or present—no surprises, just a clean, professional report.
Dogs
Older, low‑velocity epilepsy SKUs
Older, low-velocity epilepsy SKUs for Supernus show low share (under 5%) in a flat-to-declining segment, tying up inventory and commercial attention with minimal return; industry epilepsy Rx volumes have been roughly flat to down low-single-digits in recent years. Turnarounds demand costly relaunches or marketing spends and rarely sustain share gains. Consider pruning slow SKUs or bundling them into payoff-driven combos to free cash and sales capacity.
Legacy PD add‑ons facing generic pressure
Legacy PD add‑ons show minimal differentiation and face steep generic erosion; generic entry typically cuts branded volume by over 80% and prices by 60–90% within a year (IQVIA/industry benchmarks). Tough reimbursement and prescriber fatigue mean share drips away despite marketing; cash contribution is marginal relative to total portfolio. Sunset plans now outweigh heroic reinvestment.
Small legacy ADHD formulations in stimulant‑heavy niches
Small legacy ADHD formulations operate in a crowded stimulant-dominated market where generics account for over 80% of US ADHD prescriptions as of 2024. Entrenched competitors and rapid copycat launches limit pricing power; promotional spend yields minimal market-share gains. After gross-to-net impacts and PBM rebates these SKUs reach break-even at best. Recommend exit or sharply narrow focus to niche formulary pockets.
Niche hospital‑only presentations
Dogs: Niche hospital‑only presentations show tiny volumes, complex logistics and high service costs, yielding limited strategic value outside a few centers; they divert field and distribution resources better allocated to higher‑margin, broader market products, so divest or de‑prioritize.
- Low volume
- High logistics cost
- Limited strategic reach
- Recommendation: divest/de‑prioritize
Non‑core international micro‑licenses
Non-core international micro-licenses show fragmented demand and regulatory drag, delivering single-digit royalty economics (commonly 5–12% in comparable specialty pharma deals) and thin margins that often fail to cover fixed SG&A.
Management overhead and compliance costs frequently exceed payoff; without local commercial partners scaling is impractical and time-to-revenue extends beyond typical value-horizon for Supernus.
Rationalize the portfolio by exiting subscale territories and concentrating resources on high-opportunity regions and partnered deals.
- fragmented demand
- regulatory drag
- thin margins (≈5–12% royalties)
- management overhead > payoff
- hard to scale without local muscle
- recommend: rationalize portfolio
<5% share, ≈0 to -5% volumes, > 80% generics — divest
Supernus Dogs (older epilepsy SKUs, legacy PD add‑ons, small ADHD presentations, niche hospital forms, micro-licenses) show <5% share, flat-to-down volumes (≈0 to -5% recent), >80% generics in ADHD (2024), and royalty economics of ~5–12%; high logistics and SG&A erode margins—recommend divest or de‑prioritize to free cash and commercial capacity.
| Metric | Value |
|---|---|
| Avg share | <5% |
| Volume trend | ≈0 to -5% |
| ADHD generic share (2024) | >80% |
| Royalty range | 5–12% |
| Recommendation | Divest/de‑prioritize |
Question Marks
Next‑gen ADHD indications and age expansions
Next‑gen ADHD and age‑expansion targets sit in a large market—U.S. childhood ADHD diagnosis ~9.8% (CDC) and global ADHD therapeutics expected mid‑single to high‑single digit CAGR into 2024—yet share is not guaranteed. Success hinges on meaningful trial wins and payer alignment; commercialization timelines mean high burn before material revenue. Invest aggressively if robust early efficacy/safety and formulary support appear, otherwise cut fast.
New CNS pipeline assets (depression, anxiety, impulse‑control)
New CNS pipeline assets targeting depression, anxiety and impulse‑control face a large unmet need—WHO estimates over 300 million people live with depression—yet the space is crowded with mixed clinical outcomes. Differentiation must be crystal‑clear to break through formulary and prescriber barriers. Clinical and access risks are real; fund winners, partner or shelve the rest.
Digital adherence and real‑world data programs
Digital adherence and real‑world data programs can lift persistency—WHO reports average adherence to long‑term therapies around 50%—and provide payer evidence of value. Adoption is uneven and early monetization is difficult, with digital interventions showing median adherence gains near 10 percentage points in meta‑analyses. If linked to improved outcomes, RWD can tip access decisions; pilot, measure, and scale only interventions that move the needle.
Ex‑US market entries
Ex‑US market entries present clear growth runway—global pharma sales reached about $1.6 trillion in 2024—yet market access and local regulatory requirements are heavy lifts and vary by country.
Upfront costs (registrations, local trials, launches) typically outpace early revenue; selective launches can limit spend while proof points are gathered.
The right local partner can accelerate reimbursements and bend the profitability curve; pilot launches in 2–3 markets before broader expansion are recommended.
- Growth tag: global pharma ~ $1.6T (2024)
- Risk tag: high regulatory & access friction
- Cost tag: upfront launch investments > early revenue
- Strategy tag: partner-led pilots in 2–3 markets
New formulations and combo approaches
New formulations and combos could address ~50% chronic‑med adherence gaps and US nonadherence costs >$290B/year (2024), improving tolerability and market penetration; however technical/CMC risks often cause 6–18 month timeline slips. If clinical PK/PD shows clear benefits the asset can convert to a Star; stage‑gate tightly and terminate quickly if signals fade.
- Adherence upside: ~50%
- Cost context: >$290B (US, 2024)
- CMC risk: 6–18m delay
- Action: tight stage‑gate, kill fast
U.S. ADHD 9.8%, global pharma $1.6T: clinical wins, payer access
Large addressable markets (U.S. childhood ADHD 9.8% CDC; global pharma $1.6T 2024) but execution risk high; success needs clear clinical wins, payer access and durable differentiation. High upfront launch/CMC costs (> $290B US nonadherence cost context) and 6–18m timeline risk. Prioritize assets with strong early signals; partner and pilot ex‑US launches.
| Tag | Metric |
|---|---|
| Growth | U.S. ADHD 9.8%; global pharma $1.6T (2024) |
| Risk | High regulatory/access; CMC 6–18m |
| Cost | Context: US nonadherence >$290B (2024) |
| Strategy | Stage‑gate, partner pilots 2–3 markets |